Hanmi Pharm has made a license contract of immunization disease treatments with Lilly
Hanmi Pharm and Eli Lilly announced on the 19th that they have made a license and cooperation contract to develop and commercialize the Hanmi Pharm’s BTK inhibitor, HM71224, related to immunization disease.
The contract has left an approval procedure for the Hart-Scott-Rodino Antitrust Improveme...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
